Shareholders of Anthem Biosciences Limited (NSE:ANTHEM) will be pleased this week, given that the stock price is up 10% to ₹914 following its latest quarterly results. Results look mixed - while revenue fell marginally short of analyst estimates at ₹5.9b, statutory earnings were in line with expectations, at ₹10.43 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Taking into account the latest results, the consensus forecast from Anthem Biosciences' eight analysts is for revenues of ₹25.5b in 2027. This reflects a substantial 23% improvement in revenue compared to the last 12 months. Per-share earnings are expected to grow 16% to ₹12.70. Before this earnings report, the analysts had been forecasting revenues of ₹25.5b and earnings per share (EPS) of ₹12.70 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
Check out our latest analysis for Anthem Biosciences
It will come as no surprise then, to learn that the consensus price target is largely unchanged at ₹920. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Anthem Biosciences at ₹1,050 per share, while the most bearish prices it at ₹850. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. For example, we noticed that Anthem Biosciences' rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 52% growth to the end of 2027 on an annualised basis. That is well above its historical decline of 0.6% a year over the past year. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 17% per year. So it looks like Anthem Biosciences is expected to grow faster than its competitors, at least for a while.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Anthem Biosciences going out to 2029, and you can see them free on our platform here..
You can also see our analysis of Anthem Biosciences' Board and CEO remuneration and experience, and whether company insiders have been buying stock.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.